Shares of Prothena Corp. (NASDAQ:PRTA) shot up 4.8% during mid-day trading on Wednesday . The company traded as high as $54.98 and last traded at $54.10, with a volume of 263,915 shares traded. The stock had previously closed at $51.61.

A number of brokerages recently issued reports on PRTA. Zacks Investment Research upgraded Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Friday, May 6th. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Corp. in a research note on Wednesday, May 4th. Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research note on Tuesday, July 5th. Barclays PLC began coverage on Prothena Corp. in a research note on Friday, May 13th. They issued an “overweight” rating and a $60.00 target price on the stock. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Prothena Corp. currently has an average rating of “Buy” and a consensus target price of $74.60.

The company’s 50-day moving average is $44.48 and its 200 day moving average is $41.70. The stock’s market cap is $1.86 billion.

Prothena Corp. (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.04. Equities research analysts forecast that Prothena Corp. will post ($3.72) EPS for the current year.

In other Prothena Corp. news, insider Arthur W. Homan sold 9,375 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total transaction of $488,812.50. Following the transaction, the insider now owns 9,375 shares of the company’s stock, valued at $488,812.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dennis J. Selkoe sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $45.00, for a total value of $225,000.00. Following the transaction, the director now directly owns 3,025 shares in the company, valued at approximately $136,125. The disclosure for this sale can be found here.

A number of institutional investors recently added to or reduced their stakes in the company. Jennison Associates LLC raised its position in Prothena Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock worth $27,699,000 after buying an additional 1,912 shares during the period. Wells Fargo & Company MN raised its position in Prothena Corp. by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock worth $16,730,000 after buying an additional 234,667 shares during the period. California Public Employees Retirement System raised its position in Prothena Corp. by 214.0% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock worth $6,246,000 after buying an additional 62,500 shares during the period. Nationwide Fund Advisors raised its position in Prothena Corp. by 77.8% in the fourth quarter. Nationwide Fund Advisors now owns 35,835 shares of the company’s stock worth $2,441,000 after buying an additional 15,683 shares during the period. Finally, New York State Common Retirement Fund raised its position in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock worth $2,111,000 after buying an additional 1,200 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.